VivoGenie Anti-Human EGFR (Panitumumab) - Fc Reduced Biosimilar (IVMB0518)
- SKU:
- IVMB0518
- Antibody Type:
- In Vivo Biosimilar
- Endotoxin Level:
- Low Endotoxin
- Applications:
- In Vivo
- Disease Area:
- Lung Cancer
- Disease Area:
- Colorectal Cancer
Description
| Product Name: | Anti-Human EGFR (Panitumumab) |
| SKU: | IVMB0518 |
| Size: | 500 µg |
| Antibody Type: | Biosimilar Recombinant Human Monoclonal Antibody |
| Clone: | ABX-EGF |
| Target: | EGFR |
| Isotype: | Human IgG2κ |
| Host Species: | Human |
| Reactivity: | Human |
| Applications: | ELISA |
| Expression Host: | HEK-293 Cells |
| FC Effector Activity: | Muted |
| Synonyms: | Epidermal growth factor receptor, ErbB1, Anti-Human EGFR, ABX-EGF |
| Product Concentration: | ≥ 5.0 mg/ml |
| Purity: | ≥95% by SDS Page |
| Immunogen: | Human EGFR/ErbB1 |
| Endotoxin Level: | < 1.0 EU/mg as determined by the LAL method |
| Applications and Recommended Usage: | FA, ELISA, WB |
| Antigen Distribution: | EGFR is overexpressed on the cell surfaces of various tumor cell types and is also found in the plasma membranes, cytoplasm, and cell junctions of many healthy tissues, including those associated with the Skin – Epidermis development cluster of The Human Protein Atlas. EGFR is also found in the blood secretome. |
| Formulation: | This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. |
| Specificity: | This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Panitumumab. This product is for research use only. Panitumumab activity is directed against Human EGFR. |
| Additional Applications Reported In Literature: | IP FC |
Epidermal growth factor receptor (EGFR, also known as ErbB1 or HER-1) belongs to the receptor tyrosine kinase superfamily and is a transmembrane glycoprotein that activates various signaling pathways fundamental to cellular proliferation, differentiation, and survival1, 2. EGFR plays important roles during embryogenesis, organogenesis, and in the growth, differentiation, maintenance, and repair of adult tissues2. EGFR is also a host factor that facilitates viral entry for hepatitis B4, hepatitis C5, and gastroenteritis6 and plays a role in SARS-CoV-2 infection7, 8, 9.
Dysregulation, somatic mutation, and/or altered signaling of EGFR is associated with neurological diseases (e.g. Parkinson’s2, Alzheimer’s1, 2, and amyotrophic lateral sclerosis2) and multiple cancers (lung, glioblastoma, brain, breast, colorectal, ovarian)10. Additionally, in cancer, binding of ligands to EGFR is associated with aberrant cell proliferation, invasion, metastasis, angiogenesis, and decreased apoptosis11. As such, EGFR is the target of multiple cancer therapies, including monoclonal humanized antibodies, such as panitumumab, as well as selective small molecule inhibitors.
Panitumumab was generated in a XenoMouse IgG2 strain immunized with the human cervical epidermal carcinoma cell line A43112. Panitumumab binds specifically to EGFR and inhibits the growth and survival of selected human tumor cell lines over-expressing EGFR in vitro and in vivo13. Panitumumab binds EGFR with high affinity, blocking the binding of both EGF and TGF-α, and preventing EGF-activated EGFR tyrosine autophosphorylation and downstream activation of receptor-associated kinases12. Panitumumab inhibits cell growth, tumor cell activation, in vitro tumor cell proliferation12, and metastasis13. Panitumumab also induces apoptosis and decreases proinflammatory cytokine and vascular growth factor production13. Additionally, upon binding, panitumumab causes EGFR internalization in tumor cells12.
Panitumumab was approved in the United States for the treatment of some patients with EGFR-expressing metastatic colorectal cancer14, 15.
| Ligand/Receptor: | Epidermal growth factor receptor |
| State of Matter: | Liquid |
| Regulatory Status: | Research Use Only (RUO). Non-Therapeutic. |
| Product Preparation: | Recombinant biosimilar antibodies are manufactured in an animal free facility using onlyin vitroprotein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. |
| Pathogen Testing: | To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. |
| Storage and Handling: | Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. |
| UniProt: | P00533 |
| Research Area: | Biosimilars |
Related Products
VivoGenie Anti-Human EGFR (Panitumumab) Biosimilar (IVMB0517)
VivoGenie Anti-Human EGFR (Necitumumab) - Fc Reduced Biosimilar (IVMB0516)
VivoGenie Anti-EGFR (Cetuximab) Biosimilar (Fc Reduced) (IVMB0240)
VivoGenie Anti-Human IFNy (Emapalumab) - Fc Reduced Biosimilar (IVMB0493)
